XML 66 R23.htm IDEA: XBRL DOCUMENT v3.3.1.900
Segment and Geographic Information
 12 Months Ended
Dec. 31, 2015
Segment Reporting [Abstract]  
Segment and Geographic Information

14.

Segment and Geographic Information

The Company has determined that the chief executive officer is the chief operating decision maker (“CODM”). The CODM reviews financial information presented for the Company’s various clinical trial programs as well as results on a consolidated basis. License, milestone and collaboration services revenues received are not allocated to various programs for purposes of determining a profit measure and resource allocation decisions are made by the CODM based primarily on consolidated results. As such, the Company has concluded that it operates as one segment. Supplemental enterprise-wide information has been presented below.

Geographic Revenues

Geographic revenues, which are based on the bill to region, are as follows (in thousands):

 

 

 

Years Ended December 31,

 

 

 

2015

 

 

2014

 

 

2013

 

Europe

 

$

159,123

 

 

$

119,559

 

 

$

76,478

 

Japan (related party)

 

 

21,596

 

 

 

17,987

 

 

 

25,661

 

All other

 

 

109

 

 

 

55

 

 

 

31

 

Total revenue

 

$

180,828

 

 

$

137,601

 

 

$

102,170

 

 

Geographic Long-Lived Assets

Property and equipment, net by geographic location are as follows (in thousands):

 

 

 

December 31,

 

 

 

2015

 

 

2014

 

United States

 

$

113,628

 

 

$

116,099

 

China

 

 

15,392

 

 

 

16,072

 

Total property and equipment

 

$

129,020

 

 

$

132,171

 

 

Customer Concentration

Substantially all of the Company’s revenues to date have been generated from the following collaboration partners that respectively accounted for more than 10% of the Company’s total revenue and accounts receivable:

 

 

 

As of or for the Year Ended December 31,

 

 

 

Percentage of Revenue

 

 

Percentage of Accounts Receivable

 

 

 

2015

 

 

2014

 

 

2013

 

 

2015

 

 

2014

 

Astellas—Related party

 

 

12

%

 

 

13

%

 

 

25

%

 

 

29

%

 

 

37

%

AstraZeneca

 

 

88

%

 

 

87

%

 

 

75

%

 

 

71

%

 

 

63

%